Patient Derived Organoids can be derived from biopsies of unresectable cholangiocarcinomas and represent an useful tool for functional tumour characterization
AASLD LiverLearning®, Chiara Braconi, 144135
Baseline Immune Changes following DAA Therapy may Predict Early Viral Clearance
AASLD LiverLearning®, Lisa Barrett, 144391
PD-L1 expression in hepatocellular carcinoma: relationship with clinical and pathological features
AASLD LiverLearning®, Fouad LAFDIL, 144136
Functional Genomic Study Reveals GPR125 as a Novel Regulator for Hepatocyte Lipotoxicity
AASLD LiverLearning®, Robert Plummer, 144392
A Randomized, Prospective, Comparative Study about Effects and Safety of Sorafenib vs. Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis
AASLD LiverLearning®, Wang Yong Choi, 144137
Oxidized low-density lipoprotein (oxLDL) induces a pro-inflammatory/pro-fibrotic response from liver sinusoidal endothelial cells that is attenuated by activation of the nuclear bile acid receptor FXR.
AASLD LiverLearning®, Rachel McMahan, 144393
Effects of BMS-986036 (pegylated fibroblast growth factor 21) on hepatic steatosis and fibrosis in a mouse model of nonalcoholic steatohepatitis
AASLD LiverLearning®, John Krupinski, 144394
The Expression of Glypican-3 (GPC-3) in Hepatocellular Carcinoma (HCC): An Analysis of 1,643 Cases.
AASLD LiverLearning®, Guanghua Rong, 144151
A Human In Vitro Surrogate System For Studying Non-Alcoholic Steatohepatitis (NASH)
AASLD LiverLearning®, Ryan Feaver, 144407
The Role Of Serum Alphafetoprotein Determination In HCV-Cirrhosis After Antiviral Treatment
AASLD LiverLearning®, Cristina Della Corte, 144152
Pharmacological and Molecular inhibition of mTORC1 Activation Reduces Ethanol-Induced ER Stress and Ameliorates Alcoholic Liver Injury in Mice
AASLD LiverLearning®, Hanqing Chen, 144408
Development of a Novel Circulating Tumor Cells Isolation System in Patients with Hepatocellular Carcinoma Using a Microcavity Array
AASLD LiverLearning®, Kazuto Takahashi, 144153
5’AMP-activated kinase gamma-1 (AMPKγ1) Deficiency Impairs Autophagy and is Permissive for Hepatocellular Carcinoma In Vivo
AASLD LiverLearning®, Chuhan Chung, 144409
Connexin 32 is a critical gatekeeper at the nexus between inflammation and steatosis in ALD and NAFLD
AASLD LiverLearning®, Jay Luther, 144410
Predictors of Inadequate Ultrasound Quality for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis
AASLD LiverLearning®, Amit Singal, 144167
Simultaneous recruitment of Th17 cells in hepatic tissue and in intra-abdominal visceral fat of NASH patients undergoing bariatric surgery
AASLD LiverLearning®, Monika Rau, 144423
Circulating and intratumoral CD39+FoxP3+ regulatory T cells associate with disease progression in HCC patients
AASLD LiverLearning®, Junliang Fu, 144168
Reduction of Liver Fibrosis by CCR2 antagonist CCX872 in Murine Models of NASH
AASLD LiverLearning®, Zhenhua Miao, 144424
ALBI-T: A Score Based on Albumin, Bilirubin and TNM Stratifies Patients with Child A Cirrhosis and Hepatocellular Carcinoma
AASLD LiverLearning®, Imam Waked, 144169
Lysosomal Acid Lipase Activity Is Selectively Reduced In Non-Alcoholic Fatty Liver Disease
AASLD LiverLearning®, Francesco Tovoli, 144425
Obeticholic acid reduces plasma HDL-cholesterol levels and promotes transhepatic cholesterol efflux in hyperlipidemic hamsters via a mechanism involving upregulation of hepatic SR-BI
AASLD LiverLearning®, Jingwen Liu, 144426
The prognostic factors after initial RFA for primary hepatocellular carcinoma
AASLD LiverLearning®, Atsuo Takigawa, 144183
The role of cytochrome P450-2E1 in fast food-induced hepatic fibrosis
AASLD LiverLearning®, Mohamed Abdelmegeed, 144439
Birth Cohort Analysis of Incidence, Mortality, Treatment modality and Survival of Hepatocellular Carcinoma in Surveillance, Epidemiology and End Results Registries, 1973-2012
AASLD LiverLearning®, Fanggang Liu, 144184
Pharmacological inhibition of FASN Prevents High Fat Diet Induced Liver Damage in Mice and Significantly Reduces de novo Lipogenesis in Humans
AASLD LiverLearning®, Doug Buckley, 144440
Changes in tissue and blood biomarkers upon exposure to sorafenib in patients with resectable HCC: translational evaluation in the BIOSHARE trial
AASLD LiverLearning®, Valérie Paradis, 144185
Acyl-CoA Thioesterase 9 (Acot9) Suppresses Triglyceride Formation in the Liver: Implications for the Pathobiology of Hepatic Insulin Resistance in Non-alcoholic Fatty Liver Disease (NAFLD)
AASLD LiverLearning®, Baran Ersoy, 144441
Role of microRNA-206 and microRNA-133b in facilitating insulin signaling and inhibiting lipogenesis
AASLD LiverLearning®, Guisheng Song, 144442
IL-33, released with hepatectomy, facilitated CCA prognosis
AASLD LiverLearning®, Daisaku Yamada, 144199
NAFLD is Associated with Decreased Oxidation of Orally-Delivered Fatty Acids - a Palmitate Breath Test Study
AASLD LiverLearning®, Gihan Naguib, 144455
The Utility of a Multidisciplinary Liver Tumor Clinic (MDTC) to Treat Patients with Hepatocellular Carcinoma (HCC) at a Large Volume Liver Transplant Center
AASLD LiverLearning®, Ravi Vora, 144200
Impaired Mitophagy Flux Triggers NLRP3 Inflammasome Activation during Lipotoxicity in Primary Rat Hepatocytes
AASLD LiverLearning®, Ning-Ping Zhang, 144456
Impact of Age, Gender, and Race/Ethnicity on Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma in the U.S.
AASLD LiverLearning®, Vicky Bhagat, 144201
Cenicriviroc (CVC), a dual inhibitor of chemokine receptors (CCR)2 and 5, decreases hepatic inflammation by altering inflammatory macrophage populations in a mouse model of NASH
AASLD LiverLearning®, Annie Kruger, 144457
Human FGF19 but not NGM282, an Engineered Variant of FGF19, Causes Hepatocellular Carcinoma (HCC) In A Diet-Induced Mouse Model of Non-Alcoholic Steatohepatitis (NASH)
AASLD LiverLearning®, Lei Ling, 154960
An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma
AASLD LiverLearning®, Irun Bhan, 154961
Genome-wide association study identifies a TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus
AASLD LiverLearning®, Yasuhito Tanaka, 154962
Prognostic values of inflammation and immune-based scores in patients with hepatocellular carcinoma who undergo transarterial chemoembolization
AASLD LiverLearning®, Eun Ju Cho, 144215
Hepatocellular Carcinoma is Associated with Highest Inpatient Post-Operative Mortality Amongst GI Cancers
AASLD LiverLearning®, George Cholankeril, 144216
In vivo knock-down of bile salt export pump exacerbates the homeostasis of the cholesterol and bile acid metabolism in mouse NAFLD model.
AASLD LiverLearning®, Kazuya Okushin, 144472
Defining Optimal Follow-up Intervals for Hepatocellular Carcinoma: What Should the Cost-effective Standard Be?
AASLD LiverLearning®, Janice Jou, 144217
Roles of Mac-2 binding protein in the NASH liver fibrosis progression
AASLD LiverLearning®, Yusuke Ebisutani, 144473
Hepatocyte-Specific Depletion of Ubiquitin Regulatory X Domain-Containing 8 (UBXD8) Induces Marked Fibrosis in Mice Fed a Short-Term Non-Alcoholic Steatohepatitis (NASH) Model Diet
AASLD LiverLearning®, Norihiro Imai, 144474
Improvement in NASH histological activity highly correlates with fibrosis regression.
AASLD LiverLearning®, Vlad Ratziu, 154976
Significance of hepatic progenitor cell marker-positive hepatocellular carcinoma and its possible prediction by AFP-L3
AASLD LiverLearning®, Atsunori Tsuchiya, 144231
In vitro model of exercise synergizes with sorafenib through enhanced AMP-activated kinase (AMPK) signaling: A novel approach to augment effectiveness of sorafenib against hepatocellular carcinoma (HCC)
AASLD LiverLearning®, Michelle Zhang, 144232
EDP-305, A Novel and Potent Farnesoid X Receptor Agonist, Exhibits Favorable Anti-inflammatory and Anti-fibrotic Activity In Vitro
AASLD LiverLearning®, Lijuan Jiang, 144488
The Expression of SALL4 and Its Clinical Significance In Hepatocellular Carcinoma.
AASLD LiverLearning®, Zhiying Xin, 144233
Nucleotide binding and oligomerization domain like receptors (NLR) inflammasomes in patients with non-alcoholic fatty liver disease (NAFLD)
AASLD LiverLearning®, Seong Hee Kang, 144489
Comparison of liver pathology in three rodent NASH models to that observed in human NASH patients
AASLD LiverLearning®, Robert Walczak, 144490
Regional differences in admissions and treatment outcomes for patients with hepatocellular carcinoma (HCC) in Thailand: data from the national universal health care
AASLD LiverLearning®, Ml.Taya Kitiyakara, 144246
Outcome of treatment in BCLC-0/A HCC patients in real world practice: impact of treatment response and treatment stage migration in overall survival (OS)
AASLD LiverLearning®, Alessia Gazzola, 144247
Risk factors of early recurrence after curative hepatectomy in hepatocellular carcinoma
AASLD LiverLearning®, Young Mi Hong, 144248
Predictive factors of hepatocellular carcinoma and transplant-free survival in Chinese patients with primary biliary cholangitis
AASLD LiverLearning®, Ka Shing Cheung, 144249
The evaluation of endoplasmic reticulum (ER) stress in steatotic hepatocytes under a new 3D perfusion culture system consistent with hepatic portal blood.
AASLD LiverLearning®, Eiji Kakazu, 144505
Xenobiotic metabolism in a mouse model of non-alcoholic fatty liver disease: A case study of the ubiquitous environmental contaminant tetrachloroethylene
AASLD LiverLearning®, Joseph Cichocki, 144506
Genetic variant of exonuclease1 correlate with cirrhosis and hepatocellular carcinogenesis acting on dysplastic nodule.
AASLD LiverLearning®, Takumu Hasebe, 144507
PNPLA3 (rs738409 C>G) contributes to low viral load and decreased risk of hepatocellular carcinoma in HCV genotype 1b cirrhotic patients.
AASLD LiverLearning®, Sona Frankova, 144262
A failure of the past is not a determinant of future outcomes: Report of operations performed by liver transplant surgeons in patients with underlying cirrhosis.
AASLD LiverLearning®, Angel Alsina, 144263
Frailty is independently associated with increased hospitalisation days in patients on the liver transplant waitlist
AASLD LiverLearning®, Jennifer Lai, 144264
When imaging and explant pathology conflict: defining the risk of false-positive hepatocellular carcinoma in recipients transplanted with T2 MELD exceptions
AASLD LiverLearning®, Therese Bittermann, 144265
B-hydroxybutyrate protects from alcoholic hepatitis via a GPR109a-C/EBPβ dependent pathway
AASLD LiverLearning®, Yonglin Chen, 144521
The Use of HCV Positive Donors in HCV Negative Liver Transplant Recipients
AASLD LiverLearning®, George Cholankeril, 144522
Peritransplant treatment with Direct Acting Antivirals of HIV-HCV coinfected patients
AASLD LiverLearning®, Carmen Vinaixa, 144523
Outcomes of Liver Transplant from Elderly Deceased Donors in the United States
AASLD LiverLearning®, Mica Esquenazi, 144278
Liver Transplantation after Share 35: Impact on Pre- and Post-Transplant Costs and Mortality
AASLD LiverLearning®, Clara Nicolas, 144279
Living donor liver transplantation in children: an increasing survival benefit over time.
AASLD LiverLearning®, Tamir Miloh, 144280
Effects of Recipient Size and Allograft Type on Pediatric Liver Transplantation for Biliary Atresia
AASLD LiverLearning®, Sophoclis Alexopoulos, 144281
The Numbers of New Waitlist Registrants and Removals are Outpacing the Number of Liver Transplants: National Trends and Regional Variation from 2003 through 2014
AASLD LiverLearning®, Eric Orman, 144294
Rescue allocation for liver transplantation in a context of organ shortage: what is the fate of otherwise discarded grafts?
AASLD LiverLearning®, Louise Barbier, 144295
Examining unmet need: international trends in transplantation for autoimmune liver disease
AASLD LiverLearning®, Gwilym Webb, 144296
Current trends in characteristics of patients listed for liver transplantation will lead to higher rates of waitlist removal due clinical deterioration
AASLD LiverLearning®, A. Sidney Barritt IV, 144297
Real World Predictors of Hospital Readmission for Hepatic Encephalopathy after Placement of Transjugular Intrahepatic Portosystemic Shunt
AASLD LiverLearning®, Michael Rowley, 144310
Clinical Characteristics of Balloon-Occluded Retrograde Transvenous Obliteration for Refractory Hepatic Encephalopathy: A Comparison with Occlusion of Portosystemic Shunts for Gastric Varices
AASLD LiverLearning®, Tatsuro Nishimura, 144311
Temporal changes in cardiac function of cirrhotic patients: a 6-months prospective study with advanced echocardiography
AASLD LiverLearning®, Signe Wiese, 144312
Total Skeletal Muscle Compared to Psoas Muscle Evaluation for the Assessment of Sarcopenia in Cirrhosis: A Multi-Center Study from the FLEXIT Consortium
AASLD LiverLearning®, Aldo J Montano-Loza, 144313
Good glycemic control contributes to an improvement in hyperammonemia by occlusion of portosystemic shunts in cirrhotic patients with diabetes
AASLD LiverLearning®, Tsuyoshi Ishikawa, 144326
Clinial features of muscle volume loss and reduced handgrip-strength in patients with chronic liver disease
AASLD LiverLearning®, Atsushi Hiraoka, 144327
Ammonium chloride induces disturbances in the microcirculation on the surface of at brain and increased periarteriolar adenosine concentration
AASLD LiverLearning®, Peter Nissen Bjerring, 144328
Hepato-Adrenal Syndrome is Associated with Increased Length of Stay
AASLD LiverLearning®, Christina Lindenmeyer, 144329
LDV/SOF combination is associated with 100% SVR in patients with thalassemia major: a preliminary report from an Italian multicenter study
AASLD LiverLearning®, Alessandra Mangia, 144342
Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis
AASLD LiverLearning®, Natsuko Kobayashi, 144343
Clinical Pharmacokinetics of MicroRNA-122 Inhibitor RG-101 Administered as a Single Dose to Hepatitis C Virus (HCV) and Non-HCV Infected End-Stage Renal Disease (ESRD) Subjects Undergoing Hemodialysis (HD) Compared to Normal Renal Function Subjects
AASLD LiverLearning®, John Grundy, 144344
Therapeutic targeting of Hsp90 alleviates liver macrophage-specific NLRP3 inflammasome activation in alcoholic liver injury
AASLD LiverLearning®, Danielle Bullock, 144089
AT-337 and AT-511: Novel Potent and Selective Pan-genotypic Purine Nucleotide Prodrug Inhibitors of the HCV Polymerase
AASLD LiverLearning®, Steven Good, 144345
Rapid intrahepatic and peripheral blood HCV RNA decline and HCV-specific immune response increase during IFN-free DAA therapy in HCV treatment-naïve patients
AASLD LiverLearning®, Sonya MacParland, 144358
Outcomes following index hospitalization with decompensated alcohol-related cirrhosis versus severe alcoholic hepatitis; a retrospective cohort study.
AASLD LiverLearning®, Dev Katarey, 144103
Rapid changes in circulating lipid/lipoprotein and apolipoprotein profiles during daclatasvir and asunaprevir therapy in chronic hepatitis C virus, genotype 1b-infected patients
AASLD LiverLearning®, Erika Matsunaga, 144359
Absence of Perilipin 2 prevents long-chain ceramide accumulation in the LD fractions of alcohol-fed mice
AASLD LiverLearning®, Amanke Oranu, 144104
Global analysis of transcriptional changes in DAA vs. IFN-based treatment in chronic HCV identifies several shared and different pathways.
AASLD LiverLearning®, Matthew Burchill, 144360
Differential regulation of human UDP-glucuronosyltransferases (UGTs) during chronic ethanol exposure in a humanized transgenic UGT1A mouse model
AASLD LiverLearning®, Steffen Landerer, 144105
Hepatitis C virus inhibits tumor suppressor p53 via host protein kinase R-dependent mechanisms
AASLD LiverLearning®, David McGivern, 144361
Fecal microbiota transplantation (FMT) improves outcome and survival in steroid ineligible severe alcoholic hepatitis–A randomized control trial (NCT 02458079)
AASLD LiverLearning®, Cyriac Philips, 155632
Vitamin D antagonizes the expression of genes that are epigenetically regulated by Hepatitis C virus
AASLD LiverLearning®, Ran Tur-Kaspa, 144374
Alcohol Exposure Differentially Regulates Immune Responses of Liver Endothelial Cells and Hepatic Stellate Cells to E. coli Infection
AASLD LiverLearning®, Hugo Rosen, 144119
HCV Cure Decreases Markers of T Cell Exhaustion on Most Peripheral T Cell Subsets in HCV-infected Liver Transplant Patients
AASLD LiverLearning®, Erin Doyle, 144375
HBV replication increases cholesterols via upregulation of SREBP-2/HMGCR and down-regulation of CYP-7α in alcoholic fatty liver mice
AASLD LiverLearning®, Hongwu Wang, 144120
HLA-E molecule expression in the liver is associated with severity of liver disease in chronic hepatitis C
AASLD LiverLearning®, Patrícia Almeida, 144376
Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver lesions in mice
AASLD LiverLearning®, Laura WRZOSEK, 144121
Changes in NS3/4A and NS5A resistance-associated variants of hepatitis C virus after treatment failure with direct-acting antiviral(s).
AASLD LiverLearning®, Hoang Hai, 144377